Evidence map›Paper›PMID 41503581›Full record

ArticleMolecular therapy. Nucleic acids2026

Improved cross-protection and immunity against influenza A virus in mice using a novel mRNA vaccine with optimized design of RNA sequence.

Tangqi Wang, Ruiwen Han, Zhanyihao Hao, Xueting Cheng, Jia Li, Chengcheng Zhai, Junjia Guo, Donghong Wang, Yao Deng, Liang Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tangqi WangZhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Ruiwen HanZhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Zhanyihao HaoHangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Xueting ChengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing 102206, China.
Jia LiZhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Chengcheng ZhaiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing 102206, China.
Junjia GuoZhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Donghong WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing 102206, China.
Yao DengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing 102206, China.
Liang ZhangHangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Wenjie TanZhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional influenza vaccines provide strain-specific immunity, and their production can be affected by egg-culture-adapted mutations. A universal influenza vaccine with conserved antigens and novel vaccine platforms is urgently required. To induce the immune responses toward more conserved epitopes, we generated a multi-antigen influenza mRNA vaccine, lipopolyplex (LPP)-HNH mRNA, coding headless hemagglutinin stem and neuraminidase with three different sequences (HNH-ORI, HNH-E1, or HNH-E2) and delivered by LPP. The immunogenicity and protective efficacy of these single-chain mRNA vaccines against influenza A viruses were evaluated in mice models. Mice exhibited sustained and robust antibody and cellular immune responses against all three LPP-HNH mRNA vaccines, indicating that these vaccines provided mice with broad protection against H1N1, H3N2, or H5N1 influenza viruses. HNH-E1 and HNH-E2 with optimized sequence showed higher protein expression, stronger specific CD4

Indexed as

broad-spectrum mRNA vaccinehemagglutinin steminfluenza A virusMT: Delivery Strategiesneuraminidaseoptimized sequence

Identifiers

PMID41503581
PMCPMC12768920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.